Creative Biolabs Launches Comprehensive Exosome-Related Technical Services

February 21, 2025 07:00 PM GMT | By EIN Presswire
 Creative Biolabs Launches Comprehensive Exosome-Related Technical Services
Image source: EIN Presswire

Creative Biolabs offers novel approaches in exosome science through its sophisticated technology, providing unique services to clients worldwide. SHIRLEY, NY, UNITED STATES, February 21, 2025 /EINPresswire.com/ -- The progress being made in biomedical research has elevated the role of exosomes as a vital medium for intercellular communication and is progressively positioning them as critical factors in disease diagnosis, therapy, and even drug development. To enable researchers to comprehend the full biological and clinical potential of exosomes, Creative Biolabs provides a variety of exosome-related technical services supported by their unique expertise and advanced technology.

Exosome Isolation and Characterization
The first step of exosome research is exosome isolation and purification. For accurate and highly efficient exosome isolation, Creative Biolabs uses ultracentrifugation, immunoaffinity methods, and nanoparticle tracking analysis (NTA) as part of its exosome isolation services. One of the most important activities in exosome studies is exosome characterization. Clients can depend on Creative Biolabs for size, concentration, and phenotypic measurement of exosomes through fluorescence nanoparticle tracking analysis (fl-NTA) and electron microscopy (EM) techniques.

According to the exosome specialists at Creative Biolabs, "Exosome characterization by nanoparticle tracking analysis can measure the size, concentration, distribution, and other factors of exosomes, allowing reliable exosome characterization data for our clients."

Exosomal Peptidomics
The peptides and proteins serve as cellular indicators and exhibit important changes during various physiological and pathological processes. This makes them valuable for understanding disease mechanisms and creating diagnostic biomarkers.

Creative Biolabs offers complete solutions from sample collection to peptide enrichment, liquid chromatography-mass spectrometry (LC-MS) analysis and bioinformatics, enabling clients to find and understand critical exosome peptides and their action to facilitate prompt diagnosis and precision treatment of cancer, cardiovascular diseases and other conditions.

Exosomal lncRNA Sequencing
Long non-coding RNAs (lncRNAs) in exosomes are found to be important in mechanisms such as cancer resistance, metastasis, and cancer invasiveness. Creative Biolabs leverages the sophisticated SuPrecision™ system to deliver comprehensive exosomal lncRNA sequencing services, which include sample collection, library preparation, next-generation sequencing, and thorough bioinformatics assessment, helping clients target specific lncRNA molecules. "Using our precise technology to extract lncRNA from exosomes, we are confident that high-quality RNA samples are attained to provide reliable data for subsequent sequencing analysis."

"Exosomes, which are known for their role in intercellular communication, are emerging as important subjects of research in the biomedical area," said the expert. "Through exosomal peptidomics and lncRNA sequencing, we conduct detailed molecular profiling to help our clients discover novel disease biomarkers and therapeutic options."

For further details, please check https://www.creative-biolabs.com/exosome/ or contact us to get your custom service strategy.

Company Overview
Whether in fundamental studies, clinical research, or pharmaceutical development, Creative Biolabs will keep expanding the use of exosome technology and contribute greatly to improving health and treating diseases.

Candy Swift
Creative Biolabs
631-830-6441
[email protected]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next